ClinicalTrials.gg
CompletedNCT04570644Updated Mar 3, 2022

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

A Phase 1 interventional study of ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen) in Healthy Volunteers and Alzheimer Disease, sponsored by AZTherapies, Inc.. Completed at 1 site in United States. Open to participants aged 55 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by AZTherapies, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
55 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
913th of 1,609
56 · median 73
Started
2020
with 103 others
Phase 1
304 of 1,940
31 open now
Registered
1,245th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 913th largest by enrollment of the 1,609 interventional ones that give a count, is one of 104 that started in 2020, is one of 304 in phase 1, and was the 1,245th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, open-label, cross-over, pharmacokinetic and pharmacodynamic PK/PD study. (Part A)The PK portion of the study is designed to evaluate the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and ALZT-OP1b, in both plasma and CSF, following co-administration of the two active investigational products, in healthy volunteers and Alzheimer subjects aged 55-79 and in good health. (Part B) The PD portion of the study will evaluate the pharmacodynamics of ALZT- OP1, using both plasma and CSF biomarkers, following 60 days of consecutive daily treatment, in AD subjects only.

Read the detailed description

This is a phase I/II randomized, open-label, cross-over, PK/PD study. The PK (Part A) portion of the study is designed to evaluate both single and double doses of ALZT-OP-1a (17.1mg or 34.2 mg) and ALZT-OP1b (10 mg or 20 mg) in both Alzheimer's subjects and healthy volunteers. The PD (Part B) portion of the study is designed to evaluate single doses of ALZT-OP-1a (17.1mg) and ALZT-OP1b (10 mg) in AD subjects treated for 60 days. An Alzheimer's control group will be utilized for comparison to active treatment groups but will not be administered study treatment; however, they will have biomarkers collected.

PK (Part A) n=24, both healthy volunteers and AD subjects

Part A is an open-label study, cross-over, PK study where 24 subjects will be randomly assigned to receive treatment regimen A-B or B-A for two consecutive day of dosing.

Subjects will be admitted to the Phase 1 unit the morning before dosing and will initiate dosing the following morning for 2 consecutive days of dosing (A-B, or B-A).

Day 1 (A-B) will consist of a single inhaled oral dose of ALZT-OP1a via dry powder inhaler + a single oral tablet dose of ALZT-OP1b.

Day 2 (B-A) will consist of two oral inhaled doses of ALZT-OP1a, not more than 2 mins apart, via dry powder inhaler + two oral tablets doses of ALZT-OP1b.

Day 1 (B-A) will consist of two oral inhaled doses of ALZT-OP1a, not more than 2 mins apart, via dry powder inhaler + two oral tablets doses of ALZT-OP1b.

Day 2 (A-B) regimen consists of a single inhaled oral dose of ALZT-OP1a via dry powder inhaler + a single oral tablet dose of ALZT-OP1b.

AD subjects will be given the option to roll over into the PD portion of the study.

PD (Part B) n=32, AD subjects only

Part B is an open-label, PD study where 32 AD subjects will be randomly assigned to receive either active treatment or be assigned to a non-treatment control arm.

Twenty-four (24) subjects will be randomly assigned to Treatment Group 1 to receive a single (17.1 mg) inhaled dose of ALZT-OP1a plus a single (10 mg) oral dose of ALZT-OP1b daily for 60 days.

Eight (8) subjects will be randomly assigned to Treatment Group 2 (Control Group) and will not be administered study drug.

All subjects will have plasma collected on Day 1, Day 30, and Day 60 and CSF collected on Day 1 and Day 60.

03

Conditions studied

  • Healthy Volunteers
  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For All Subjects

    1. Provide a signed written ;
    2. Age 55-79 old (inclusive);
    3. without abnormal, findings;
    4. (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2
    5. Negative urine drug screen for selected drugs of abuse at screening;
    6. Negative for hepatitis and at screening;
    7. Negative for COVID-19 at screening;
    8. Good general health, as determined by medical history, physical examination, and clinical laboratory testing;
    9. Must provide written informed consent for CSF sampling. For AD Subjects Only

      In addition to satisfying all of the above inclusion criteria, AD subjects must also meet the following criteria:

    10. Diagnosed with mild to moderate Alzheimer's disease;
    11. Clinical Dementia Rating (Global) 0.5
    12. (MMSE) ≤ 22;
    13. Must be fluent in the language of the cognitive testing material being administered;
    14. Stability of permitted medications for 4 weeks prior to study start;
    15. Visual and auditory acuity adequate for neuropsychological testing.
    16. Must provide written informed consent for APOe4 genotype testing; For All Subjects in Part A (PK)
    17. Willingness to stay in the unit overnight for the duration of the PK portion of the study.

Exclusion criteria

Exclusion Criteria:

  • For All Subjects

    1. Current smokers, or ex-smokers with a remote history (> 100 pack/year);
    2. medical conditions;
    3. History of abnormal clinically significant abnormalities;
    4. Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing;
    5. Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in absence of febrile episodes, in the last 14 days;
    6. History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism, and excretion of drugs;
    7. , regardless of location;
    8. disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis;
    9. agents are prohibited one month prior to entry and for the duration of the trial;
    10. Currently taking medications known to be CYP2C9 inducers (e.g., carbamazepine and rifampicin;
    11. Currently taking cromolyn, or have taken cromolyn products, within the past 30 days;
    12. Non-steroidal anti-inflammatory drug (NSAID) use (products containing ibuprofen while on study);
    13. Allergy or to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.);
    14. Allergy or hypersensitivity to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin, including Stevens-Johnson syndrome;
    15. History of hypersensitivity or allergies to any of the drug compound under investigation (cromolyn sodium, ibuprofen, lactose, or magnesium stearate);
    16. Current respiratory disorders and chronic respiratory disease with impaired respiratory effort or difficulty taking inhaled drugs (examples: , emphysema);
    17. Abnormal pulmonary function test, defined for this protocol as: \< 70% of predicted value, indicating moderate or severe respiratory impairment;
    18. Any other disease or condition, which, in the opinion of the investigator, would make the subject unsuitable for this study;
    19. Female subjects of with a positive pregnancy test (urine or serum) or who are pregnant or lactating.

      For AD Subjects Only

      In addition to not meeting any of the above exclusion criteria for Normal Healthy Volunteers, AD subjects must also not meet any of the following criteria:

    20. Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities;
    21. Major depressive episode, as described in the (DSM-V) within the past 6 months, which could lead to difficulty complying with the protocol;
    22. History of schizophrenia or bipolar disorder (DSM-V criteria);
    23. Currently taking medications that could lead to difficulty complying with the protocol; For All Subjects in Part A (PK)
    24. Aspirin, or products containing aspirin, while on PK study; For All Subjects in Part B (PD)
    25. Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses, while on PD study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Other
    Part A

    24 subjects randomized to receive treatment: (A-B) = Single 17.1 mg oral inhaled dose of ALZT-OP1a (cromolyn) via dry powder inhaler and a single oral 10 mg tablet of ALZT-OP1b (ibuprofen) on Day 1. On Day 2, subjects would receive two 17.1 mg doses of ALZT-OP1a via dry powder inhaler and two 10 mg tablets of ALZT-OP1b (ibuprofen), within two minutes of each other. (B-A) = Two 17.1 mg doses of ALZT-OP1a (cromolyn) and two doses of 10 mg ALZT-OP1b (ibuprofen) on Day 1 and single 17.1 mg dose of ALZT-OP1a cromolyn 17.1 mg and a single 10 mg dose of ALZT-OP1b (ibuprofen) on Day 2. All subjects will have plasma and CSF collected for PK analysis.

    Drug: ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)

  • Other
    Part B

    PD - 32 subjects (AD only) will be enrolled in the PD portion of the study. Twenty-four (24) subjects will be assigned to Treatment Group 1 to receive a single (17.1 mg) inhaled dose of ALZT-OP1a (cromolyn) plus a single (10 mg) oral dose of ALZT-OP1b (ibuprofen) daily for 60 days. All subjects will have plasma and CSF collected for PD biomarker analysis. Eight (8) A subjects will be assigned to Treatment Group 2 (Control Group) and will not be administered study drug.

    Drug: ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)

Interventions

  • DrugALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)

    Drug page: Cromolyn

    Drug : ALZT-OP1a 1. Mast cell stabilizer 2. Neuroinflammatory microglial modulator ALZT-OP1b anti-inflammatory Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study.

    Also known as: Cromolyn, Intal, Cromolyn Sodium, Sodium cromoglycate, Ibuprofen

06

What researchers measure

Primary outcomes

  1. Part A Non-compartmental PK parameters will be calculated and reported for ALZT-OP1a and ALZT-OP1b

    • PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF

    Time frame: • 2 Days

  2. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF AUC 0-∞

    Evaluation AUC 0-∞ (area under the curve from 0 to infinity)

    Time frame: 2 Days

  3. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF AUC 0-t

    Evaluation AUC 0-t (area under the curve from 0 to t hours where t is the last measured concentration)

    Time frame: 2 Days

  4. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF AUCPLASMA/AUCCSF

    Evaluation AUCPLASMA/AUCCSF (ratio at 60 min, 120 min, 240 min, 360 min and 480 min)

    Time frame: 2 Days

  5. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF CL/F

    Evaluation CL/F (apparent total body clearance)

    Time frame: 2 Days

  6. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF Cmax

    Evaluation Cmax (maximum plasma and CSF concentration observed)

    Time frame: 2 Days

  7. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF t½ (half-life)

    Evaluation t½ (half-life)

    Time frame: 2 Days

  8. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF tmax

    Evaluation tmax (sampling time at which Cmax occurred)

    Time frame: 2 Days

  9. PK profile for ALZT-OP1a and ALZT-OP1b in plasma and CSF Vd/F

    Evaluation Vd/F (apparent volume of distribution)

    Time frame: 2 Days

Secondary outcomes

  1. Biomarker Beta Amyloid (Αβ-42) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Beta Amyloid (Αβ-42)

    Time frame: Day 1 to Day 60

  2. Biomarker Beta Amyloid (Αβ-40) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Beta Amyloid (Αβ-40)

    Time frame: Day 1 to Day 60

  3. Biomarker Beta Amyloid (Αβ-38) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Beta Amyloid (Αβ-38)

    Time frame: Day 1 to Day 60

  4. Biomarker Total Tau Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Total Tau

    Time frame: Day 1 to Day 60

  5. Biomarker Neurofilament light (Nf-L) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Neurofilament light (Nf-L)

    Time frame: Day 1 to Day 60

  6. Biomarker Glial Fibrillary Acidic Protein (GFAP) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Glial Fibrillary Acidic Protein (GFAP)

    Time frame: Day 1 to Day 60

  7. Biomarker P-Tau (Thr 231) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation P-Tau (Thr 231)

    Time frame: Day 1 to Day 60

  8. Biomarker Interferon-γ (IFN-γ) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Interferon-γ (IFN-γ)

    Time frame: Day 1 to Day 60

  9. Biomarker Tumor Necrosis Factor-α (TNF-α) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Tumor Necrosis Factor-α (TNF-α)

    Time frame: Day 1 to Day 60

  10. Biomarker Transforming Growth Factor-β1 (TGF-β1) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Transforming Growth Factor-β1 (TGF-β1)

    Time frame: Day 1 to Day 60

  11. Biomarker CD33 Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation CD33

    Time frame: Day 1 to Day 60

  12. Biomarker Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Triggering Receptor Expressed on Myeloid Cells-2 (TREM2)

    Time frame: Day 1 to Day 60

  13. Biomarker Neurogranin Sample Analysis plasma and CSF Day 1 to 60 Days

    Evaluation Neurogranin

    Time frame: Day 1 to Day 60

Other outcomes

  1. Number of Treatment Emergent Adverse Events (TEAE)

    Safety will be evaluated based on the number, type, and frequency of treatment emergent adverse events. They will be individually presented for all subjects in data listings, and summarized in tables by treatment group and by treatment assignment. The AEs will be summarized and reported collectively based on information obtained through physical examination, ECG, and laboratory findings captured after dosing was initiated.

    Time frame: 2 Days Part A and 60Days Part B

07

Study locations

1 site
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jan 2021, 4 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2020
First posted
Sep 30, 2020
StartActual
Aug 28, 2020
Primary completionActual
Jan 18, 2021
CompletionActual
Jan 18, 2021
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04570644
Lead sponsor
AZTherapies, Inc.
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Aug 28, 2020
Primary completion
Jan 18, 2021
Completion
Jan 18, 2021
Last update
Mar 3, 2022

Study contacts

David R. Elmaleh, PhD
study chair · AZTherapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cromolyn

Start the discussion